• Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
Friday, March 24, 2023
No Result
View All Result
SUBSCRIBE
The Outlooker
27 °c
Delhi
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
No Result
View All Result
The Outlooker
No Result
View All Result
  • National
  • Politics
  • Opinion
  • Business
  • Science
  • World
  • Health
Home Business

Cement – Q1FY22 Preview: Resilient performance expected in quarter

by The Outlooker Web Desk
July 9, 2021
in Business
0
Cement – Q1FY22 Preview: Resilient performance expected in quarter
1.8k
SHARES
12.9k
VIEWS
Share on FacebookShare on Twitter

Average pan-India prices up 6% q-o-q during Q1FY22 led by 11% q-o-q rise in East and 6-7% q-o-q increase in South and West.

While YoY as well as q-o-q comparison in Q1FY22e is not meaningful given the varying degree of lockdown/restrictions due to Covid, industry is expected to post ~45% y-o-y growth in volumes with almost stable Ebitda/te y-o-y on a reported basis. On a q-o-q basis, volumes are expected to be down ~20% q-o-q vs usual ~10% q-o-q decline, while average Ebitda/te may rise 8-9% q-o-q despite cost escalations. We expect average realisation to rise 5% q-o-q (Rs 230/te) and 2.6% y-o-y (Rs 130/te) and total cost/te to increase ~3% both q-o-q and y-o-y (Rs 120/te).

Consensus earnings are yet again likely to be upgraded given better-than-expected prices sustaining to date in seasonally weak monsoon necessitated by cost escalations. Our coverage universe FY22-23e Ebitda is 8-10% ahead of consensus. SRCM & UTCEM remain our top picks. We also like ACEM, JKCE and TRCL. Key risks: Lower demand/prices and any regulatory intervention.

Industry volumes expected to grow 45% y-o-y/decline 20% q-o-q during Q1FY22e to 85mnte with pan-India utilisation at ~70%. West and South regions are likely to lead volume growth on y-o-y basis on a low base. Similarly, non-trade demand is likely to be better on a y-o-y basis led by higher infrastructure demand. JKCE is likely to lead with ~70% y-o-y volume growth while UTCEM/ ACEM may see 50-55% y-o-y growth.

Average pan-India prices up 6% q-o-q during Q1FY22 led by 11% q-o-q rise in East and 6-7% q-o-q increase in South and West. Prices in North and Central regions are up 3-4% q-o-q. On a y-o-y basis, average pan-India prices are likely up ~2.5% y-o-y. Non-cement revenues including RMC, white cement/ putty, etc are likely to be down >30% q-o-q owing to Covid-induced restrictions.

Overall cost/te may increase ~3% both q-o-q and y-o-y as sharp increase in variable costs are likely to be partially offset by better cost efficiencies. Average domestic pet coke prices are up 11% q-o-q and 85% y-o-y, while imported coal prices are up 16% q-o-q and 60% y-o-y. Similarly, average diesel prices are up ~7% q-o-q and ~30% y-o-y.

Average Ebitda/te may rise 9% q-o-q (~Rs 100/te) and 2% y-o-y to Rs 1,353/te for our coverage universe. Ebitda growth is likely to be strong at 40-70% y-o-y for most companies under our coverage. TRCL is likely to lead with Ebitda/te of >Rs 1,600/te followed by SRCM and DALBHARA at ~Rs 1,500/te.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

The Outlooker is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

The Outlooker Web Desk

The Outlooker Web Desk

Next Post
90 Cases Of Delta Plus Variant Of COVID-19 Reported In Tripura

90 Cases Of Delta Plus Variant Of COVID-19 Reported In Tripura

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Johnson and Johnson Loses Key Tuberculosis Drug Patent In India
National

Johnson and Johnson Loses Key Tuberculosis Drug Patent In India

March 24, 2023
Vandalism At Indian High Commission In London Raised In UK Parliament
National

Vandalism At Indian High Commission In London Raised In UK Parliament

March 23, 2023
Rahul Gandhi Can Be Disqualified, Say Congress Sources: 10 Points
National

Rahul Gandhi Can Be Disqualified, Say Congress Sources: 10 Points

March 23, 2023
Opposition Alleges “Conspiracy” As Rahul Gandhi Convicted For Defamation
National

Opposition Alleges “Conspiracy” As Rahul Gandhi Convicted For Defamation

March 23, 2023

Connect with us

No Result
View All Result

Archives

  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020

Category

  • Artistic
  • Business
  • Crypto
  • Design
  • Entertainment
  • Fashion
  • featured
  • Food
  • Gaming
  • Health
  • Human
  • Lifestyle
  • Movie
  • Music
  • National
  • Opinion
  • Politics
  • Science
  • Spaces
  • Sports
  • Tech
  • Travel
  • Uncategorized
  • World

Recent Posts

  • Johnson and Johnson Loses Key Tuberculosis Drug Patent In India
  • Vandalism At Indian High Commission In London Raised In UK Parliament
  • Rahul Gandhi Can Be Disqualified, Say Congress Sources: 10 Points

About Us

The Outlooker

The Outlooker is your source of authentic, hand-picked news, stories, analysis from India & the World.

  • Terms Of Service
  • Privacy Policy
  • About us
  • Submit your story
  • Contact

© 2019-2021 The Outlooker. All rights reserved.

No Result
View All Result
  • Home
  • Politics
  • World
  • Business
  • Science
  • National
  • Entertainment
  • Gaming
  • Movie
  • Music
  • Sports
  • Fashion
  • Lifestyle
  • Travel
  • Tech
  • Health
  • Food

© 2019-2021 The Outlooker. All rights reserved.